Avtor/Urednik		Fokter, Samo K
Naslov		Vpliv etidronata na periprotetično mineralno kostno gostoto po artroplastiki kolka
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2005
Obseg		str. 92
Jezik		slo
Abstrakt		Introduction: Periprosthetic bone loss is identified after inserting a hip prosthesis and is often a result of stress shielding or altered loading of the proximal femur. Depending on the severity, the bone loss may threaten the prosthesis survival. Bisphosphonates like etidronate potentially decrease bone resorption and are clinically useful for the treatment of many metabolic diseases characterized by increased bone loss. The Hypothesis. After hip arthroplasty, treatment of patients with etidronate would cause diminished periprosthetic bone loss and decreased rate of bone turnover compared to patients receiving placebo. The effect of etidronate would be pronounced in patients treated with endoprosthesis because of femoral neck fracture than in patients treated with endoprosthesis because of hip osteoarthritis. Materials and Methods: The current study investigated the effect of cyclic etidronate therapy on periprosthetic and contralateral bone mineral density (BMD) in an one-year, prospective, randomized, placebo-contoled, double-blind study on 46 patients after cemented hip arthroplasty. Fifteen patients were treated with partial hip arthroplasty because of sustained hip fracture, and 31 patients were treated with total hip arthroplasty because of osteoarthritis. Etidronate was administered orally in a regimen repeated every 14 weeks and periprosthetic BMD was measured with dual energy X-ray absorptiometry (DXA) in the total periprosthetic area and in the seven Gruen Zones at 1 week (baseline), 6 weeks, 3 months, 6 months, and 12 months postoperatively. Ln addition, biochemical markers of bone turnover including bone-specific alkaline phosphatase (bAP), osteocalcin and cross-linked Ctelopeptides of type-1 collagen (CTX) were measured from serum-separated blood in 32 patients (69,6%) at 1 week (baseline), 6 and 12 months postoperatively. (Abstract truncated at 2000 characters)
Deskriptorji		HIP PROSTHESIS BONE DENSITY ETIDRONATE DISODIUM FEMORAL NECK FRACTURES OSTEOARTHRITIS, HIP